資源描述：
《中晚期卵巢癌術(shù)后順鉑腹腔聯(lián)合紫杉醇靜脈化療的臨床觀察.pdf》由會員上傳分享，免費在線閱讀，更多相關(guān)內(nèi)容在應(yīng)用文檔-天天文庫。
1、茅偉，等中晚期卵巢癌術(shù)后順鉑腹腔聯(lián)合紫杉醇靜脈化療的臨床觀察《臨床應(yīng)用研究／論著l中晚期卵巢癌術(shù)后順鉑腹腔聯(lián)合紫杉醇靜脈化療的臨床觀察茅偉，邱慧敏，余根培，錢紅，王輝，劉衛(wèi)星，許青同濟大學(xué)附屬第十人民醫(yī)院腫瘤科，上海200072【摘要】目的：觀察順鉑腹腔聯(lián)合紫杉醇靜脈化療治療中晚期卵巢癌術(shù)后患者的臨床療效和安全性。方法：回顧性分析我院2006一O1—2009—12行細胞減滅術(shù)Ⅱ～Ⅳ期卵巢癌76例患者，順鉑腹腔聯(lián)合紫杉醇靜脈化療36例為治療組，并以同期行順鉑聯(lián)合紫杉醇靜脈化療患者4O例作為對照。比較兩組患者無進展生存期(PFS)、生存率和不良反應(yīng)。結(jié)果：治療組PFS27個月，
2、對照組PFS23個月，P<0．05。治療組l、2和3年生存率分別為97．22(35／36)、94．44(34／36)和88．88％(32／36)，對照組1、2和3年生存率分別為95．。0(38／40)、90．O0(36／40)和77．5O％(31／40)。治化療組嘔吐及腎功能損傷低于對照組，而腹痛高于對照組。結(jié)論：順鉑腹腔聯(lián)合紫杉醇靜脈化療治療中晚期卵巢癌術(shù)后患者可延長患者PFS及生存率，毒副反應(yīng)輕，值得臨床應(yīng)用。中華腫瘤防治雜志，2012，19(5)：372—374【關(guān)鍵詞】卵巢腫瘤／外科學(xué)；卵巢腫瘤／藥物療法；藥物療法，聯(lián)合ClinicalefectofpOstOper
3、atiVeintraperitOneaIchemotherapywithcisplatincombinedwithintravenouspaclitaxelchemotherapyforthemoderatelyoradvancedovariancancerMAOWei，QIUHui—min，y【，Gen—pei，QIANHong，WANGHui，LJUWei—xing，XUQingDepartmentofOncology，No．10People’SHospitalofTongJiUniversity，Shanghai200070，P．R．China[ABSTRACT]OB
4、JECTIVE：Toobservetheclinicalefficacyandsafetyofpostoperativeintraperit0nea1chemotherapywithcisplatincombinedwithintravenouspaclitaxelchemotherapyforthemoderatelyoradvancedovariancancer．METH—ODS：FromJan．2006toDec．2009，76patientswithovariancancerin1I—IVstageaftercytoreductivesurgerywereana—l
5、yzedretrospective1y．And36ovariancancerpatientsweretreatedwithintraperitonealcisplatinchemotherapyandintrave—nouspaclitaxelchemotherapy(treatmentgroup)．Totally40ovariancancerpatientsacceptedintravenouschemotherapywithcisplatinandpaclitaxel(controlgroup)．Theprogressionfreesurvival(PFS)，survi
6、valrateandadversereactionoftwogroupswereobserved．RESULTS：ThePFSintreatmentgroupwas27months，ThePFSincontrolgroupwas23months，thedifferenceswassignificant(P<0．05)．One，twoandthreeyearsurviva1ratesintreatmentandcontrolgroupwere97．22(35／36)，94．44(34／36)and88．88(32／36)respectively，thatinIVgroupwe
7、re95．O0(38／40)，9O．OO(36／40)and77．50％(31／40)respectively．Vomitingandrenalfunctionfailurewasobviouslylowerandstomach—achewasobviouslyhigherinintraperitonealandintravenouschemotherapygroupthanthecontrolgroup．CONCLUSION：Thepostoperativeintraperitonealcisplatinchem
